Yousif Capital Management LLC Sells 8,909 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Yousif Capital Management LLC reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 156,232 shares of the company’s stock after selling 8,909 shares during the quarter. Yousif Capital Management LLC’s holdings in Roivant Sciences were worth $1,848,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. Covestor Ltd raised its position in shares of Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after purchasing an additional 1,605 shares during the last quarter. US Bancorp DE boosted its stake in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Quarry LP grew its position in Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Gladius Capital Management LP bought a new stake in Roivant Sciences during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total value of $4,971,637.20. Following the completion of the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,980,391.35. This trade represents a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,942,629 shares of company stock valued at $23,034,486. Insiders own 7.90% of the company’s stock.

Roivant Sciences Trading Down 2.8 %

Shares of ROIV stock opened at $10.49 on Wednesday. Roivant Sciences Ltd. has a 12-month low of $9.76 and a 12-month high of $13.06. The stock has a market capitalization of $7.64 billion, a P/E ratio of 1.86 and a beta of 1.25. The firm’s 50 day moving average is $11.48 and its 200 day moving average is $11.60.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. As a group, equities analysts predict that Roivant Sciences Ltd. will post -1.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.